Manisha H. Shah

Oncology

320 W 10th Ave
Columbus, OH 43210

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 93 publications

Response to Letter to the Editor From Zhang et al: "Cabozantinib Plus Ipilimumab/Nivolumab in Patients with Previously Treated Advanced Differentiated Thyroid Cancer".

Response to Letter to the Editor From Zhang et al: "Cabozantinib Plus Ipilimumab/Nivolumab in Patients with Previously Treated Advanced Differentiated Thyroid Cancer".

Journal: The Journal of clinical endocrinology and metabolism

Published: March 17, 2025

Whole-Exome Sequencing Reveals High Prevalence of Germline Alterations in Neuroendocrine Neoplasms.

Whole-Exome Sequencing Reveals High Prevalence of Germline Alterations in Neuroendocrine Neoplasms.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: July 05, 2024

Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer.

Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer.

Journal: The Journal of clinical endocrinology and metabolism

Published: April 05, 2024

Telomere-lengthening germline variants predispose to a syndromic papillary thyroid cancer subtype.

Telomere-lengthening germline variants predispose to a syndromic papillary thyroid cancer subtype.

Journal: American journal of human genetics

Published: November 26, 2023

Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.

Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.

Journal: PloS one

Published: August 17, 2023

Coronary Artery and Peripheral Vascular Disease in a Patient with Poorly Differentiated Thyroid Cancer Treated with the Tyrosine Kinase Inhibitor Lenvatinib.

Coronary Artery and Peripheral Vascular Disease in a Patient with Poorly Differentiated Thyroid Cancer Treated with the Tyrosine Kinase Inhibitor Lenvatinib.

Journal: Case reports in endocrinology

Published: June 22, 2023

Inhibition of Bruton's tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors.

Inhibition of Bruton's tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors.

Journal: JCI insight

Published: February 24, 2023

Kinase inhibitors in thyroid cancers.

Kinase inhibitors in thyroid cancers.

Journal: Endocrine oncology (Bristol, England)

Published: December 13, 2022

Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).

Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 19, 2022

A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors.

A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors.

Journal: Endocrine-related cancer

Published: October 07, 2022

Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial.

Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial.

Journal: The Lancet. Oncology

Published: September 20, 2022

Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study.

Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study.

Journal: Cancer

Published: July 20, 2022

Showing 1-12 of 93

Last Updated: 09/26/2026